TOPADUR Pharma AG is a Swiss biopharmaceutical start-up based in Schlieren, Zurich. The company was founded in 2015 by experienced scientists that combine several years of expertise in R&D Pharma. TOPADUR’s vision is to improve patients’ quality of life by providing highly effective and safe drugs for unmet medical conditions.
TOPADUR has discovered and developed new dual-acting drugs that target the cGMP-Enzyme Regulation System to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. Based on our key invention we have developed an attractive portfolio of drug candidates to treat aging-related diseases like chronic wounds, skin fibrosis, age-related macular degeneration, colorectal cancer, hair loss and skin aging.
TOPADUR has discovered and developed new dual-acting drugs that target the cGMP-Enzyme Regulation System to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. Based on our key invention we have developed an attractive portfolio of drug candidates to treat aging-related diseases like chronic wounds, skin fibrosis, age-related macular degeneration, colorectal cancer, hair loss and skin aging.
Location: Switzerland, Zurich, Schlieren
Employees: 11-50
Founded date: 2015
Investors 1
| Date | Name | Website |
| 26.10.2023 | VentureLab | venturelab... |
Mentions in press and media 40
| Date | Title | Description |
| 18.12.2025 | Executive reshuffle in ICT and Biotech startups | Payment provider Payrexx AG has appointed Anja Traum to the position of CEO effective 1 January 2026 to guide the company through its upcoming expansion phase. With a team of 50 employees, a transaction volume of CHF 1 billion, and average... |
| 31.10.2025 | More than 20 Swiss biotech companies to exhibit at Bio Europe | Bio-Europe, the leading partnering conference for the global biotechnology industry, is held annually to connect biotech, pharma, investors, and service providers through one-to-one meetings, presentations, and panels. It serves as a leadi... |
| 15.10.2025 | Industry veterans join Lifesciences and fashion-tech startups | MetaLead Therapeutics, a spinoff of the University of Zurich, has developed a novel metal-binding peptide platform to create best-in-class therapeutics that target pathological metals, restore healthy balance, or deliver therapeutic counte... |
| 24.09.2025 | Business and clinical advancements propel Swiss biotech companies | Topadur is currently conducting a Phase 2a clinical trial evaluating TOP-N53 in patients with systemic sclerosis-related digital ulcers, a rare, life-threatening autoimmune disease characterized by fibrosis, vascular damage, and chronic di... |
| 08.11.2024 | Bio-Europe: Switzerland's Biotech Showcase in Stockholm | The heart of Europe beats strong in Stockholm this November. Bio-Europe, the continent's premier partnering event for the life sciences, is back for its 30th edition. This year, it promises to be a melting pot of innovation, collaboration, ... |
| 08.11.2024 | Management transitions with industry veterans | FELFEL, the provider of smart 'FELFEL' refrigerators and its coffee offering 'Gavetti' in the corporate catering market, has appointed Raphael Gugerli as Chief Executive Officer, effective January 6th, 2025. He will succeed Anna Grassler, ... |
| 05.11.2024 | Bio Europe in Stockholm hosts 33 Swiss companies | Currently in its 30-year-edition, BIO-Europe remains Europe's leading partnering event, for the life sciences ecosystem, providing an exceptional opportunity to explore the latest trends learn and connect with potential partners. The past ... |
| 06.06.2024 | Oshen supports Topadur in the development of a treatment for alopecia | Androgenic alopecia is the most common form of hair loss in both men and women. According to data published by the Journal of Clinical and Diagnostic Research, around 60% of the global population has hair thinning problems and pattern hair... |
| 06.05.2024 | Innosuisse funded 45 Start-up innovation projects | With the Start-up innovation project, Innosuisse directly funds high potential science-based projects initiated by Swiss start-ups, giving them a financial boost to propel their market entry. The innovation projects must be based on applic... |
| 22.12.2023 | Clinical progress for three Biotechs |
Show more